Under construction – not a live service
Sign in
Taking people in DenmarkNo phase

Assessment of Residual Congestion in Acute Decompensated Heart Failure

Key facts

Where
Aarhus, Copenhagen, and Roskilde, DenmarkSee the 3 sites

Where in Denmark

  • Aarhus University Hospital - Department of CardiologyAarhus, DenmarkTaking people
  • Copenhagen University Hospital, Amager and Hvidovre Hospital - Department of CardiologyCopenhagen, DenmarkNot yet recruiting
  • Zealand University Hospital - Department of CardiologyRoskilde, DenmarkNot yet recruiting

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Aarhus University Hospital
Trial code
NCT07682298
Record updated
7 July 2026
Original description
DESIGN:Read full original descriptionShow less

DESIGN:

A prospective, multicenter, observational cohort study including 580 patients admitted for acute decompensated heart failure (ADHF).

Ultrasound assessment of congestion (VExUS and LUS) will be performed serially during admission: within 48 hours of admission, at the time diuretic therapy is switched from intravenous to oral, and on the day of discharge. The discharge assessment will serve as the primary predictor.

Treating physicians will be blinded to all ultrasound findings. Patients will be followed for 90 days by telephone follow-up and chart review for the primary endpoint, with extended chart review at one year for selected secondary endpoints.

AIMS:

To determine whether combined ultrasound assessment of venous (VExUS) and pulmonary congestion (LUS) at discharge predicts heart failure readmission and all-cause mortality in patients hospitalized with ADHF.

HYPOTHESIS:

Abnormal VExUS and/or LUS findings at discharge are associated with a higher risk of heart failure readmission and all-cause mortality after 90 days.

Inclusion: Adults (≥18 years) admitted with ADHF; Clinical evidence of congestion during admission, indicated by ≥1 of the following: pitting peripheral edema, ascites, elevated jugular venous pressure, or radiologic/ultrasound evidence of pulmonary congestion; Treatment with ≥40 mg i.v. furosemide or equivalent dose loop diuretic during admission.

Exclusion: Pregnancy; Moribund; Solitary kidney; Inability to provide written consent.

ClinicalTrials.gov NCT07682298